Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[PDF][PDF] Exploring future perspectives and pipeline progression in vaccine research and development.
Introduction. The COVID-19 pandemic had a profound impact on vaccines' Research and
Development, on vaccines' market, and on immunization programmes and policies. The …
Development, on vaccines' market, and on immunization programmes and policies. The …
Preclinical immune efficacy against SARS-CoV-2 beta B. 1.351 variant by MVA-based vaccine candidates
P Perez, G Albericio, D Astorgano, S Flores… - Frontiers in …, 2023 - frontiersin.org
The constant appearance of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved …
CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved …
[HTML][HTML] Myocarditis Associated with COVID-19 Vaccination
K Florek, M Sokolski - Vaccines, 2024 - mdpi.com
Myocarditis after the COVID-19 vaccine is one of the important adverse events following
immunization, observed mainly after mRNA-based vaccines. Importantly, post-vaccination …
immunization, observed mainly after mRNA-based vaccines. Importantly, post-vaccination …
[HTML][HTML] Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
J Corominas, C Garriga, A Prenafeta, A Moros… - Vaccine, 2025 - Elsevier
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-
inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V …
inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V …
[PDF][PDF] Innovations and Challenges in the Development of COVID-19 Vaccines for a Safer Tomorrow
Vaccination, a historically effective public health intervention, has shielded millions from
various diseases. Lessons from severe acute respiratory syndrome coronavirus (SARS …
various diseases. Lessons from severe acute respiratory syndrome coronavirus (SARS …
Immunogenicity and safety of an Omicron XBB. 1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial
MJ López Fernandez, S Narejos, A Castro… - medRxiv, 2024 - medrxiv.org
Background Global COVID-19 vaccination adapts to protect populations from emerging
variants. This communication presents interim findings from the new Omicron XBB adapted …
variants. This communication presents interim findings from the new Omicron XBB adapted …
[HTML][HTML] Omicron XBB. 1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results
MJ López Fernández, S Narejos, A Castro… - Vaccines, 2024 - mdpi.com
(1) Background: The global coronavirus disease 2019 vaccination adapts to protect
populations from emerging variants. This communication presents interim findings from the …
populations from emerging variants. This communication presents interim findings from the …
Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months
MJ Lopez, MM Vazquez, M Alvarez, JR Arribas… - medRxiv, 2024 - medrxiv.org
Abstract Background Phase IIb HIPRA-HH-2 study results showed that PHH-1V as first
booster dose elicited a strong and sustained neutralising antibody response against various …
booster dose elicited a strong and sustained neutralising antibody response against various …
[SITAATTI][C] Vacunación frente al SARS-CoV-2 en otoño de 2023:¿ a quién y cómo hay que vacunar?
FAM Llop, MC Martí - Vacunas: investigación y práctica, 2023 - dialnet.unirioja.es
[SITAATTI][C] Autumn 2023 SARS-CoV-2 immunization: who should be vaccinated and how?
F Moraga-Llop, M Campins-Martí - Vacunas (English Edition), 2023 - Elsevier